Cormedix Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cormedix Inc. on April 5, 2013, covering events occurring on April 5, 2013, and April 11, 2013. The company is a Delaware corporation headquartered in Bridgewater, NJ, focused on medical device development.
Key Financial Metrics and Material Changes
The filing does not provide specific revenue, profit, cash flow, or margin figures for the current period. However, it references the company's Form 10-K for the fiscal year ended December 31, 2012, which disclosed:
- Stockholders' equity of less than $2 million as of December 31, 2012.
- Losses from continuing operations and/or net losses in two of the three most recent fiscal years.
Material Transaction: On April 11, 2013, the company amended a 2008 License and Assignment Agreement with ND Partners, LLC. The amendment delays a $500,000 milestone payment (triggered by CE Marking issuance) by up to 12 months. In consideration, Cormedix issued ND Partners a warrant to purchase 125,000 shares of common stock at an exercise price of $1.50 per share, exercisable immediately with a five-year term.
Outlook, Risks, and Contingencies
Delisting Risk: On April 5, 2013, Cormedix received notice from NYSE MKT LLC that it failed to meet continued listing standards under Section 1003(a)(i) of the Company Guide due to low stockholders' equity and sustained losses. The company is also subject to ongoing conditions from a prior notice dated April 20, 2012, regarding substantial losses and impaired financial condition (Section 1003(a)(iv)).
Compliance Plan: Cormedix must submit a compliance plan to NYSE MKT by May 6, 2013, to regain compliance by October 20, 2013. Failure to meet these standards or make progress consistent with the plan will result in delisting proceedings.
Investor Verification Checklist
- Verify the exact stockholders' equity figure as of December 31, 2012, in the filed Form 10-K.
- Confirm the status of the CE Marking for the licensed product to determine if the $500,000 milestone payment obligation has been triggered.
- Review the upcoming compliance plan submission to NYSE MKT (due May 6, 2013) for details on capital raising or operational improvements.
- Assess the dilution impact of the 125,000-share warrant issued to ND Partners.